Mortality after urgent versus elective transcatheter aortic valve replacement: a systematic review and meta-analysis using reconstructed individual patient data from Kaplan-Meier curves

紧急经导管主动脉瓣置换术与择期经导管主动脉瓣置换术后死亡率比较:基于Kaplan-Meier曲线重建的个体患者数据的系统评价和荟萃分析

阅读:2

Abstract

BACKGROUND: Urgent transcatheter aortic valve replacement (TAVR), performed during unplanned hospitalizations, is linked to worse outcomes compared with elective TAVR. However, temporal trends in mortality remains poorly understood. This study aimed to compare survival after urgent versus elective TAVR using a reconstructed individual patient data (IPD) meta-analysis. METHODS: PubMed, Embase, and Scopus were searched through August 2025. Studies reporting Kaplan-Meier (KM) survival curves for urgent versus elective TAVR were included. Survival data were digitally extracted from published KM curves, and IPD were reconstructed algorithmically using a two-stage approach. Kaplan-Meier curves and Cox frailty models estimated survival and hazard ratios (HRs). Landmark analysis at one-year post-procedure and restricted mean survival time (RMST) were also employed to compare survival. RESULTS: Eleven studies including 77,108 patients were identified. Kaplan-Meier curves were available for 76,108 patients (urgent: 5,683; elective: 71,425) and used for reconstructed IPD analysis. Urgent TAVR was associated with higher early mortality (HR 1.83, 95% CI: 1.73-1.93; p < 0.001), with convergence beyond one year (HR 1.01, 95% CI: 0.84-1.22; p = 0.83). RMST analysis demonstrated a 6.5-month overall survival advantage in favor of elective TAVR (p = 0.001). CONCLUSIONS: Urgent TAVR is associated with significantly increased early mortality compared with elective TAVR. These findings highlight the prognostic implications of procedural timing and support early referral for elective intervention in patients with severe AS.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。